Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Completion of Patient Enrollment of TREAKISYM® Phase II Trial

Published: Wednesday, March 06, 2013
Last Updated: Wednesday, March 06, 2013
Bookmark and Share
Completion of enrollment in frontline low-grade non-Hodgkin’s lymphoma and mantle cell lymphoma patients.

SymBio Pharmaceuticals Limited has announced the completion of patient enrollment of its Phase II clinical trial of TREAKISYM® (bendamustine hydrochloride, SyB L-0501) in frontline low-grade non-Hodgkin’s lymphoma (NHL) and mantle cell lymphoma (MCL) patients in Japan.

This randomized trial is evaluating the combination of TREAKISYM® and rituximab versus R-CHOP.

SymBio initiated this multicenter open-label Phase II trial as a line extension study for TREAKISYM® in November, 2011, in collaboration with Eisai.

Completion of patient enrollment in this trial has occurred. “Thus far the study has progressed smoothly with no serious adverse events being reported,” said Fuminori Yoshida, President and CEO of SymBio. Trial results with data analysis and evaluation will be finalized as soon as possible.

In partnership with Eisai Co., Ltd. (Eisai), SymBio received marketing approval of TREAKISYM® (SyB L-0501) in October, 2010, for the treatment of patients with relapsed/refractory low-grade NHL and MCL in Japan.

The number of low-grade non-Hodgkin’s lymphoma patients in Japan is estimated to be approximately 11,000, including 4,000 refractory/relapsed patients and 7,000 untreated patients.

Currently, R-CHOP is prescribed as a standard therapy, however, clinical trial results in the U.S. and Europe have shown superiority of the combination of rituximab and bendamustine (R-B) over R-CHOP in terms of safety and efficacy, leading to the inclusion of R-B in the National Comprehensive Cancer Network (NCCN) guidelines, which are used by US physicians in prescribing oncology drugs.

SymBio has also initiated development of TREAKISYM® in refractory/relapsed intermediate and high-grade non-Hodgkin’s lymphoma, and refractory/relapsed multiple myeloma.

The Company also continues to pursue other indications in the hematology setting in order to maximize the potential of this ‘pipeline within a molecule’ and address other unmet medical needs.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SymBio Initiates Japanese Phase I Trial of Oral Rigosertib (SyB C-1101) in Frontline MDS
U.S. FDA has granted orphan drug designation for the use of rigosertib in MDS.
Thursday, July 25, 2013
SymBio Initiates Japanese Phase II Trial for TREAKISYM®
Company has commenced enrollment for bendamustine in CLL patients.
Friday, May 10, 2013
CTN Accepted for SymBio’s Japan Phase 1 Trial of Rigosertib (SyB L-1101)
U.S. FDA grants orphan drug designation for using rigosertib in MDS and pancreatic cancer.
Thursday, September 27, 2012
SymBio Initiates Japan Phase 2 Trial of Bendamustine HCl (SyB L-0501) in MM
Company has achieved first patient enrollment and start phase 2 clinical trial on December 26.
Tuesday, December 27, 2011
Onconova Presents Phase I Data for Oral Rigosertib at the 53rd ASH Annual Meeting
Oral rigosertib (ON 01910.Na) advancing to Phase II.
Wednesday, December 14, 2011
SymBio Completes Patient Enrollment for Mantle Cell Lymphoma in Bendamustine Phase II Clinical Study
The Company intends to collect efficacy and safety data in preparation for NDA filing.
Monday, July 07, 2008
Scientific News
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!